Advanced Solid Malignancies Clinical Trials

6 recruiting

Advanced Solid Malignancies Trials at a Glance

6 actively recruiting trials for advanced solid malignancies are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in Richmond, San Francisco, and Chengdu. Lead sponsors running advanced solid malignancies studies include AstraZeneca, Biocity Biopharmaceutics Co., Ltd., and Bristol-Myers Squibb.

Browse advanced solid malignancies trials by phase

Treatments under study

About Advanced Solid Malignancies Clinical Trials

Looking for clinical trials for Advanced Solid Malignancies? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Solid Malignancies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Solid Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 1

Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors

Advanced Solid MalignanciesAdvanced Solid Tumor Malignancies
West China Hospital12 enrolled1 locationNCT06927297
Recruiting
Phase 1Phase 2

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Advanced Solid Malignancies
AstraZeneca695 enrolled33 locationsNCT05417594
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies
Biocity Biopharmaceutics Co., Ltd.180 enrolled1 locationNCT07368478
Recruiting
Phase 1Phase 2

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies
Georgiamune Inc111 enrolled11 locationsNCT06028074
Recruiting
Phase 1Phase 2

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

Advanced Solid TumorAdvanced Solid Malignancies
Zhuhai Yufan Biotechnologies Co., Ltd267 enrolled5 locationsNCT05315167